[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BRPI0608376A8 - composição de ligação, método de uso de uma composição de ligação, e, kit de detecção - Google Patents

composição de ligação, método de uso de uma composição de ligação, e, kit de detecção

Info

Publication number
BRPI0608376A8
BRPI0608376A8 BRPI0608376A BRPI0608376A BRPI0608376A8 BR PI0608376 A8 BRPI0608376 A8 BR PI0608376A8 BR PI0608376 A BRPI0608376 A BR PI0608376A BR PI0608376 A BRPI0608376 A BR PI0608376A BR PI0608376 A8 BRPI0608376 A8 BR PI0608376A8
Authority
BR
Brazil
Prior art keywords
binding composition
detection kit
binding
composition
compositions
Prior art date
Application number
BRPI0608376A
Other languages
English (en)
Inventor
Edward Jones Bryan
Matthew Marquis David
Duane Dickinson Graig
Dean Watkins Jeffry
Davies Julian
Huang Lihua
Edward Vaillancourt Peter
William Rowlinson Scott
Tang Ying
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BRPI0608376A2 publication Critical patent/BRPI0608376A2/pt
Publication of BRPI0608376A8 publication Critical patent/BRPI0608376A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)

Abstract

composição de ligação, metodo de uso de uma composição de ligação, e, kit de detecção. são fornecidos anticorpos específicos para tgf beta 1 madura mais do que para tgf beta 2 madura e tgf beta 3 madura. os anticorpos compreendem cdr3 da cadeia pesada gyrx1x2x3y em que xl é w ou a, x2 é f ou l, x3 é a, e ou y.
BRPI0608376A 2005-04-22 2006-04-20 composição de ligação, método de uso de uma composição de ligação, e, kit de detecção BRPI0608376A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67408205P 2005-04-22 2005-04-22
US60/674082 2005-04-22
PCT/US2006/014943 WO2006116002A2 (en) 2005-04-22 2006-04-20 Tgf beta 1 specific antibodies

Publications (2)

Publication Number Publication Date
BRPI0608376A2 BRPI0608376A2 (pt) 2010-11-16
BRPI0608376A8 true BRPI0608376A8 (pt) 2018-10-16

Family

ID=37192643

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0608376A BRPI0608376A8 (pt) 2005-04-22 2006-04-20 composição de ligação, método de uso de uma composição de ligação, e, kit de detecção

Country Status (23)

Country Link
US (2) US7619069B2 (pt)
EP (1) EP1874818B1 (pt)
JP (1) JP5070200B2 (pt)
KR (1) KR100978684B1 (pt)
CN (1) CN101163719A (pt)
AT (1) ATE505489T1 (pt)
AU (1) AU2006240056B2 (pt)
BR (1) BRPI0608376A8 (pt)
CA (1) CA2607448C (pt)
CY (1) CY1111518T1 (pt)
DE (1) DE602006021292D1 (pt)
DK (1) DK1874818T3 (pt)
EA (1) EA016038B1 (pt)
ES (1) ES2361269T3 (pt)
HR (1) HRP20110334T1 (pt)
IL (1) IL186775A (pt)
NO (1) NO20076003L (pt)
PL (1) PL1874818T3 (pt)
PT (1) PT1874818E (pt)
RS (1) RS51845B (pt)
SI (1) SI1874818T1 (pt)
UA (1) UA93201C2 (pt)
WO (1) WO2006116002A2 (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2737519A1 (en) * 2008-09-29 2010-04-01 Centocor Ortho Biotech Inc. Anti-cd147 antibodies, methods, and uses
EP2811036A3 (en) * 2008-11-22 2015-02-18 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2010077831A1 (en) * 2008-12-16 2010-07-08 Tod Lauerman Targeted cytokine for treatment of diseases
EP4378482A3 (en) 2009-01-09 2024-09-25 Seagen Inc. Dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates
WO2012129330A1 (en) 2011-03-23 2012-09-27 Option Pharmaceutical, Llc Targeted cytokine for treatment of musculoskeletal diseases
MY192843A (en) * 2011-06-03 2022-09-12 Xoma Technology Ltd Antibodies specific for tgf-beta
EA037797B1 (ru) 2011-10-25 2021-05-21 Протена Байосайенсиз Лимитед Состав антитела, пригодный для профилактики и лечения амилоидоза, его варианты и способ его получения
WO2013134365A1 (en) 2012-03-08 2013-09-12 Ludwig Institute For Cancer Research Ltd TGF-β1 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF
US10259626B2 (en) 2012-03-08 2019-04-16 Selig Sealing Products, Inc. Container sealing member with protected security component and removal tab
PL2888283T3 (pl) 2012-08-24 2019-03-29 The Regents Of The University Of California Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
EP3816625A1 (en) 2013-05-06 2021-05-05 Scholar Rock, Inc. Compositions and methods for growth factor modulation
MX2016010674A (es) * 2014-02-19 2016-11-08 Merck Patent Gmbh Inmunoterapia con interleucina (il-12) dirigida al cancer.
EP3244926B8 (en) 2015-01-14 2024-08-21 The Brigham and Women's Hospital, Inc. Treatment of cancer with anti-lap monoclonal antibodies
TWI733661B (zh) 2015-03-04 2021-07-21 美商健臻公司 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體
TWI726870B (zh) 2015-03-04 2021-05-11 美商健臻公司 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體
JP2019511911A (ja) 2016-02-17 2019-05-09 ノバルティス アーゲー Ｔｇｆベータ２抗体
CN109415734B (zh) * 2016-02-26 2022-08-19 西安大略大学 抗CD11d抗体及其用途
JP2019509737A (ja) * 2016-03-11 2019-04-11 スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． ＴＧＦβ１結合性免疫グロブリンおよびその使用
KR20190007026A (ko) 2016-05-17 2019-01-21 제넨테크, 인크. 면역요법에서의 진단 및 사용을 위한 기질 유전자 특질
US10688181B2 (en) 2016-06-27 2020-06-23 The Regents Of The University Of California Cancer treatment combinations
WO2018043734A1 (en) * 2016-09-05 2018-03-08 Chugai Seiyaku Kabushiki Kaisha Anti-tgf-beta 1 antibodies and methods of use
WO2018204374A1 (en) 2017-05-02 2018-11-08 Merck Sharp & Dohme Corp. Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
WO2019045086A1 (ja) * 2017-08-29 2019-03-07 林化成株式会社 活性型もしくは潜在型ＴＧＦ−β１特異的抗体の用途
US11230601B2 (en) 2017-10-10 2022-01-25 Tilos Therapeutics, Inc. Methods of using anti-lap antibodies
JP7544597B2 (ja) 2017-11-06 2024-09-03 ジェネンテック， インコーポレイテッド がんの診断及び療法
JP2021529557A (ja) 2018-06-29 2021-11-04 ジェンサン バイオファーマ、 インコーポレイテッドＧｅｎｓｕｎ Ｂｉｏｐｈａｒｍａ， Ｉｎｃ． 抗腫瘍免疫チェックポイント調節因子アンタゴニスト
JP2022504839A (ja) 2018-10-10 2022-01-13 ティロス・セラピューティクス・インコーポレイテッド 抗ｌａｐ抗体変異体及びその使用
EA202192130A1 (ru) 2019-01-30 2021-12-28 Сколар Рок, Инк. Специфичные к ltbp-комплексу ингибиторы tgf и их применение
EP3990116A1 (en) 2019-06-28 2022-05-04 Gensun Biopharma Inc. ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFß1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD
MX2022008609A (es) 2020-01-11 2022-11-10 Scholar Rock Inc Inhibidores de tgf¿ y uso de los mismos.
WO2021142448A2 (en) 2020-01-11 2021-07-15 Scholar Rock,Inc. Tgf-beta inhibitors and use thereof
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
EP4348260A2 (en) 2021-06-03 2024-04-10 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
AU2022294100A1 (en) * 2021-06-18 2024-02-01 Genzyme Corporation Anti-tgf-beta antibody formulations and their use
WO2023288277A1 (en) 2021-07-14 2023-01-19 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgfb1 and uses thereof
WO2023080900A1 (en) 2021-11-05 2023-05-11 Genentech, Inc. Methods and compositions for classifying and treating kidney cancer
WO2024077095A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating bladder cancer
WO2024077166A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating lung cancer
WO2024187051A1 (en) 2023-03-07 2024-09-12 Scholar Rock, Inc. Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
US7368111B2 (en) 1995-10-06 2008-05-06 Cambridge Antibody Technology Limited Human antibodies specific for TGFβ2
CA2358400C (en) 1999-01-05 2012-05-15 Nancy A. Noble Methods for treating conditions associated with the accumulation of excess extracellular matrix
US7763580B2 (en) 1999-01-05 2010-07-27 University Of Utah Research Foundation Methods for treating conditions associated with the accumulation of excess extracellular matrix
US6492497B1 (en) * 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
JP2006525362A (ja) 2003-04-30 2006-11-09 ジェンザイム コーポレーション 腎機能不全を治療するためのＴＧＦ−βアンタゴニストとレニン−アンジオテンシン−アルドステロン系アンタゴニストとの併用
WO2005010049A2 (en) * 2003-07-09 2005-02-03 Eli Lilly And Company Tgf-beta1 ligands
MXPA06011199A (es) 2004-03-31 2007-04-16 Genentech Inc Anticuerpos anti-tgf-beta humanizados.
WO2005120437A2 (en) 2004-06-04 2005-12-22 Genentech, Inc. Method for treating lupus
WO2007041635A2 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties

Also Published As

Publication number Publication date
UA93201C2 (ru) 2011-01-25
CA2607448C (en) 2014-11-18
EA200702278A1 (ru) 2008-08-29
JP2008538564A (ja) 2008-10-30
WO2006116002A3 (en) 2007-02-01
CA2607448A1 (en) 2006-11-02
ATE505489T1 (de) 2011-04-15
EP1874818A2 (en) 2008-01-09
IL186775A0 (en) 2008-02-09
KR20070114220A (ko) 2007-11-29
HRP20110334T1 (hr) 2011-06-30
IL186775A (en) 2013-03-24
AU2006240056A1 (en) 2006-11-02
BRPI0608376A2 (pt) 2010-11-16
JP5070200B2 (ja) 2012-11-07
CN101163719A (zh) 2008-04-16
DK1874818T3 (da) 2011-06-14
WO2006116002A9 (en) 2007-07-19
AU2006240056B2 (en) 2012-02-16
RS51845B (en) 2012-02-29
PT1874818E (pt) 2011-05-05
CY1111518T1 (el) 2015-08-05
SI1874818T1 (sl) 2011-08-31
PL1874818T3 (pl) 2011-09-30
US7619069B2 (en) 2009-11-17
EA016038B1 (ru) 2012-01-30
US20080050375A1 (en) 2008-02-28
ES2361269T3 (es) 2011-06-15
US20100040633A1 (en) 2010-02-18
DE602006021292D1 (de) 2011-05-26
US8128927B2 (en) 2012-03-06
EP1874818B1 (en) 2011-04-13
WO2006116002A2 (en) 2006-11-02
KR100978684B1 (ko) 2010-08-31
NO20076003L (no) 2008-01-22

Similar Documents

Publication Publication Date Title
BRPI0608376A8 (pt) composição de ligação, método de uso de uma composição de ligação, e, kit de detecção
WO2006116127A3 (en) Compositions for use in identification of bacteria
WO2007086904A3 (en) Compositions for use in identification of adenoviruses
CY2018013I1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
WO2006094238A3 (en) Compositions for use in identification of adventitious viruses
ATE548374T1 (de) 2'-fluor-2'-desoxytetrahydrouridine als cytidindeaminaseinhibitoren
WO2007118222A3 (en) Compositions for the use in identification of fungi
PH12015501848A1 (en) Binding agents
EP1943348A4 (en) COMPOSITIONS, METHODS AND KITS FOR AMPLIFICATION OF NUCLEIC ACIDS
MY174493A (en) Binding agents
EP2460828A3 (en) Antibodies and diagnostics
NO20092611L (no) Krystallinsk faststoff Rasagilin base
NO20081287A (no) Brenselsammensetning og fremgangsmåte for å fremstille denne
WO2008118626A3 (en) Inhibitors of jnk and methods for identifying inhibitors of jnk
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
DE602006013151D1 (de) Verfahren zur herstellung von polymermaleimiden
AR059445A1 (es) Composiciones de antimicoticos ramnolipidicos y metodos de uso relacionados
EP1836214A4 (en) COMPOSITIONS, METHODS, AND KITS FOR IMPROVING PROTEIN EXPRESSION, SOLUBILITY, AND ISOLATION
MX2007013470A (es) Forma purificada de tanaproget.
EP1938781A4 (en) DENTAL VULCANIZABLE COMPOSITION AND KIT FOR SUCH A VULCANIZABLE DENTAL COMPOSITION
WO2008127839A3 (en) Compositions for use in identification of bacteria
WO2004073738A3 (de) Zusammensetzung zur verabreichung an ein lebewesen und verfahren zur markierung von mittlen
WO2009148995A3 (en) Compositions for use in identification of adventitious viruses
EA200601117A1 (ru) Малеат ибопамина, способ его получения и фармацевтические композиции на его основе
WO2006027835A1 (ja) ゲノム解析方法

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO NO ORIGINAL, TRASLADO OU FOTOCOPIA AUTENTICADA.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2510 DE 12-02-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.